You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How quickly is Kisunla™ (donanemab-azbt) eliminated from the body?
The elimination half-life of Kisunla (donanemab) is approximately 12.1 days.
See important safety information, including boxed warning, in the attached prescribing information.
Additional Pharmacokinetic Characteristics
Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.1
Donanemab has a
- half-life of approximately 12.1 days, and
- clearance of 0.0255 L/h.1
Accumulation of less than 1.3 fold occurs with every-4-week dosing.1
Enclosed Prescribing Information
Reference
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 07, 2023